TY - JOUR
T1 - Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity
AU - Sangaletti, Sabina
AU - Tripodo, Claudio
AU - Santangelo, Alessandra
AU - Castioni, Nadia
AU - Portararo, Paola
AU - Gulino, Alessandro
AU - Botti, Laura
AU - Parenza, Mariella
AU - Cappetti, Barbara
AU - Orlandi, Rosaria
AU - Tagliabue, Elda
AU - Chiodoni, Claudia
AU - Colombo, Mario P.
PY - 2016/9/27
Y1 - 2016/9/27
N2 - The extracellular matrix (ECM) contributes to the biological and clinical heterogeneity of breast cancer, and different prognostic groups can be identified according to specific ECM signatures. In high-grade, but not low-grade, tumors, an ECM signature characterized by high SPARC expression (ECM3) identifies tumors with increased epithelial-to-mesenchymal transition (EMT), reduced treatment response, and poor prognosis. To better understand how this ECM3 signature is contributing to tumorigenesis, we expressed SPARC in isogenic cell lines and found that SPARC overexpression in tumor cells reduces their growth rate and induces EMT. SPARC expression also results in the formation of a highly immunosuppressive microenvironment, composed by infiltrating T regulatory cells, mast cells, and myeloid-derived suppressor cells (MDSCs). The ability of SPARC to induce EMT depended on the localization and suppressive function of myeloid cells, and inhibition of the suppressive function MDSCs by administration of aminobisphosphonates could revert EMT, rendering SPARC-overexpressing tumor cells sensitive to Doxil. We conclude that that SPARC is regulating the interplay between MDSCs and the ECM to drive the induction of EMT in tumor cells.
AB - The extracellular matrix (ECM) contributes to the biological and clinical heterogeneity of breast cancer, and different prognostic groups can be identified according to specific ECM signatures. In high-grade, but not low-grade, tumors, an ECM signature characterized by high SPARC expression (ECM3) identifies tumors with increased epithelial-to-mesenchymal transition (EMT), reduced treatment response, and poor prognosis. To better understand how this ECM3 signature is contributing to tumorigenesis, we expressed SPARC in isogenic cell lines and found that SPARC overexpression in tumor cells reduces their growth rate and induces EMT. SPARC expression also results in the formation of a highly immunosuppressive microenvironment, composed by infiltrating T regulatory cells, mast cells, and myeloid-derived suppressor cells (MDSCs). The ability of SPARC to induce EMT depended on the localization and suppressive function of myeloid cells, and inhibition of the suppressive function MDSCs by administration of aminobisphosphonates could revert EMT, rendering SPARC-overexpressing tumor cells sensitive to Doxil. We conclude that that SPARC is regulating the interplay between MDSCs and the ECM to drive the induction of EMT in tumor cells.
KW - aminobisphosphonates
KW - Breast cancer
KW - COX-2
KW - CXCL12
KW - cyclooxygenase-2
KW - ECM
KW - EMT
KW - epithelial to mesenchymal transition
KW - extracellular matrix
KW - G-CSF
KW - GM-CSF
KW - granulocyte colony-stimulating factor
KW - granulocyte-macrophage colony-stimulating factor
KW - MDSC
KW - myeloid-derived suppressor cells
KW - SPARC
UR - http://www.scopus.com/inward/record.url?scp=84989906726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989906726&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2016.08.075
DO - 10.1016/j.celrep.2016.08.075
M3 - Article
AN - SCOPUS:84989906726
SN - 2211-1247
VL - 17
SP - 233
EP - 248
JO - Cell Reports
JF - Cell Reports
IS - 1
ER -